Travere Therapeutics insider Jeffrey A. Meckler exercised Options for 20,000 shares on 2026-09-10 at $17.44 to $26.52 per share. Investors can see the resulting ownership positions after the related transactions: 91,500 shares remained, while derivative securities ownership fell to 0.
Key Highlights
- Jeffrey A. Meckler sold 20,000 Travere Therapeutics shares across four transactions at $65.39 to $68.09 per share.
- Meckler owned 111,500 shares after exercising the options and 91,500 shares after the sales.
- The transactions left Meckler with 0 derivative securities.
Option Exercise and Share Sales
The exercise was divided across two transactions. The same date also included four transactions coded S, representing sales of 20,000 shares at prices ranging from $65.39 to $68.09 per share. Meckler’s exercise transactions covered 20,000 derivative securities at $0 per share. The transactions were reported for Jeffrey A. Meckler, an insider of Travere Therapeutics (NASDAQ: TVTX). The exercise prices and sale prices were disclosed separately for their respective transaction groups.
Ownership After the Transactions
Meckler owned 111,500 shares after the option exercises. His reported share ownership stood at 91,500 after the sales. The derivative securities position following the transactions was 0. The reported ownership figures show the share position after each transaction group. The option exercise and sale activity were both dated 10 September 2026.
FAQs
Q: What did the Travere Therapeutics insider transaction involve?
A: Jeffrey A. Meckler exercised options for 20,000 Travere Therapeutics shares across two transactions on 10 September 2026, at $17.44 to $26.52 per share.
Q: How many Travere Therapeutics shares did Jeffrey Meckler sell?
A: Meckler sold 20,000 Travere Therapeutics shares across four transactions. The disclosed sale prices ranged from $65.39 to $68.09 per share.
Q: What was Jeffrey Meckler’s ownership after the TVTX transactions?
A: Meckler owned 111,500 shares after exercising the options and 91,500 shares after the sales. His derivative securities position was 0.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.